Targeting this pathway by limiting TREM2 shedding through ADAM10/17 inhibition may represent a promising therapeutic approach for mitigating adipose tissue inflammation and systemic metabolic dysfunction associated with obesity. Here, TREM2 is linked to obesity disorder.